RecruitingPhase 3NCT04557462
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- LNP023(drug)
- Enrollment
- 540 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2021 – 2032
Study locations (30)
- AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona, United States
- Kaiser Permanente, San Diego, California, United States
- North America Research Institute, San Dimas, California, United States
- University of Colorado Anschutz, Aurora, Colorado, United States
- Nephrology Associates PA, Newark, Delaware, United States
- CaRe Research, Chubbuck, Idaho, United States
- Nep Assoc of Northern Illinois, Hinsdale, Illinois, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Clin Rsrch Consult a JCCT Company, Kansas City, Missouri, United States
- DaVita Clinical Research, Las Vegas, Nevada, United States
- New Jersey Kidney Care, Jersey City, New Jersey, United States
- Col Uni Med Center New York Presby, New York, New York, United States
- Dallas Renal Group, Dallas, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04557462 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital